Axol Bioscience Ltd.

It's that time of the year again, we're still as busy as ever over at Axol HQ, with our scientists working round the clock to handle the influx of customer requests in time for the holiday season! But even in the midst of the hustle and bustle, and the cold, we have had a couple of new updates this month to share with you. Our key November highlights included: 1. Reaching 9K+ followers on LinkedIn 2. Axol goes live on LinkedIn with a 2-part webinar series 3. Our acquisition of Phenocell driving the creation of the first in vitro model for Dry Age-related Macular Degeneration 4. An exclusive interview with our Chief Scientific Officer, Ashley Barnes, from ELRIG Drug Discovery 2024 is now live 5. Publication Round-up 6. Our upcoming conferences You will find more details on each of these in our November Newsletter below. Enjoying the content? Make sure to subscribe to our newsletter- we now have over 3,000 subscribers! #iPSCs #StemCells #MonthlyNewsletter #Acquisition

We are happy to be collaborating with Bio-Connect BV, one of our distribution partners making our products more readily available to researchers in the Benelux region. It was great to see our Senior Scientific Support Manager Dr. Steven Broadbent and Products Account Manager Priscilla Paizakis, spend some time with the Bio-Connect team. Bio-Connect have a team of experts that enables them not only just to act as a supplier but as a partner to researchers. Bio-Connect will be delivering our iPSC products throughout the Benelux region and we are pleased to be working with them. At Axol Bioscience, we are committed to empowering our partners with the tools they need to succeed, as we work together to advance scientific research with human iPSCs. We look forward to seeing the continued growth and success of our collaboration with Bio-Connect. #iPSC #ScientificInnovation #AxolBioscience #Collaboration #Biopharma

'Tis the season to be thankful...So what are you thankful for? We are thankful for Collaboration. This Thanksgiving, we’re taking a moment to reflect on the incredible progress we’ve made through the various collaborations that we have been a part of this year. It’s through these collaborations that we’ve been able to make meaningful strides in serving our community and work towards building better models of human diseases. The collaborations we have been a part of remind us of how it takes an industry-wide effort to make significant progress in the field. We’re excited for the continued partnerships and collaborations that lie ahead. From all of us at Axol Bioscience, we wish you all a Happy Thanksgiving. We certainly feel very thankful for our supportive community too. #Thanksgiving #HappyThanksgiving #Collaboration #iPSCs #Innovation #ScientificCommunity #Biopharma

Join us at the 35th International Symposium on ALS/MND in December where we will be presenting key characterization data of our iPSC-derived motor neuron disease model for ALS drug discovery. We are just over a week a way from the 35th International Symposium on ALS/MND (6th-8th December) and we are looking forward to meeting you and other fellow members of the community. We won't be coming empty handed, our new poster "Characterization of human iPSC-derived motor neuron disease model for ALS drug discovery" will be coming along with us. As we know, characterization data is crucial for ensuring the reliability and reproducibility of human iPSC models. This poster provides the opportunity to share the characterization data we have done with our iPSC-derived motor neuron disease model for ALS as part of the ongoing effort to build a better human-relevant model of this disease. Our team will be on Booth 11, flying the flag for human iPSCs and how we're supporting the ALS drug discovery industry at large. Come and talk to us, if you are interested in seeing some of this characterization data and hearing how our axoCells can support your ALS research needs! Alternatively, you can also email us at operations@axolbio.com. #ALS #humaniPSCs #drugdiscovery #collaboration #ALSMontreal

Join our Senior Scientific Support Manager Steven Broadbent in an upcoming 2-part webinar to learn about how iPSCs can be used to achieve physiologically relevant human disease models. As we know, neurodegenerative diseases are a major global health issue, yet the drug development process is notoriously slow with 99.6% of potential new therapies for Alzheimer's Disease (AD) alone failing and thus, not reaching the market. With such high failure rates, there is an urgent need for better human-relevant models of such diseases in order to de-risk drug discovery and improve the bench-to-clinic translation gap. Human iPSCs provide the opportunity to overcome obstacles that exist in the clinical translation of potential therapies for these diseases and in an upcoming 2-part webinar, starting on Wednesday 20th November, our Senior Scientific Support Manager Dr. Steven Broadbent will be speaking about how iPSCs can be used to achieve this. As world leaders in manufacturing iPSCs consistently and at scale, we wanted to provide the opportunity for our community to ask questions and learn more about the power iPSCs can have even in the midst of the lingering complex challenges that exist within drug development for neurodegenerative diseases. Here is what will be discussed in both webinars: 1st Webinar: ·      iPSCs and the pursuit of ‘more human relevant’ models ·      Building in vitro models – best practice around lines, cells, assays ·      The challenge of translational relevance of iPSCs in more complex disease models 2nd Webinar: Practical case studies such as ·      ALS - Motor neurons and neuro-muscular junction models ·      Alzheimer’s Disease complex co-culture models Register for the first webinar here: https://lnkd.in/ePc82PUy Register for the second webinar below. If you have any questions, contact us at operations@axolbio.com. #iPSCs #StemCells #CompleCoCulture #DiseaseModels #Webinar

Pushing the bounds of science can only be achieved through collaborations like this and we are proud to have partnered with Bi/ond in achieving this significant milestone in cardiac tissue engineering. By leveraging our axoCells™ Ventricular Cardiomyocytes and the Bi/ond MUSbit™ platform, they were able to successfully establish protocols to generate and characterize human 3D cardiac muscle tissues that closely mirror human heart tissue. This opens up new doors for cardiac research, drug discovery, and cardiac toxicology studies. This collaboration showcases our commitment to providing iPSC-derived cells such as axoCells™ Ventricular Cardiomyocytes, to build better human models of disease. Such models can help us better understand the pathophysiology of disease as well as screen for potentially harmful agents in the drug development process. We're excited to continue working with Bi/ond to continue to push the boundaries of scientific research and enable more accurate studies of heart function and drug responses to be done in an enhanced human-relevant platform. Watch the video below to see their 3D cardiac model in action. If you'd like to learn more about how you could use our iPSC-derived ventricular cardiomyocytes to power your cardiac-related research, contact us at operations@axolbio.com. #CardiacResearch #3DModeling #iPSCs #DrugDiscovery #ScientificInnovation #CollaborationinAction

Join us today at 4pm (BST) for the 2nd part of our 2-part live webinar series titled "The challenge of reproducing complex disease models in iPSC-derived cells. Axol’s development of complex disease models" presented by Dr. Steven Broadbent. In this LinkedIn live event, Dr. Steven will be detailing some of the practical case studies we have done specifically in Amyotrophic Lateral Sclerosis and AD in creating these more complex physiologically relevant human disease models. We look forward to sharing our work and journey so far in supporting the development of better in vitro models for neurodegenerative diseases such as Alzheimer's Disease and ALS. It is not too late to register. Register below. Not able to make it? Don't worry, you can still reach out to us at operations@axolbio.com. We'll be happy to help. #iPSCs #learnwithAxol #Neurodegenerativeresearch #AlzheimersDisease #ALS #linkedInlive

Join us tomorrow at 4pm (BST) for the 2nd part of our 2-part live webinar series "The challenge of reproducing complex disease models in iPSC-derived cells? Axol’s development of complex disease models" presented by Dr. Steven Broadbent. In this webinar, Dr. Steven Broadbent will be detailing some of the practical case studies we have done specifically in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (AD) in creating more complex physiologically relevant human disease models using iPSCs. Dr. Steven Broadbent is the Senior Scientific Support Manager here at Axol Bioscience. With a background in neuroscience, 20 years experience as an Electrophysiologist in the cardiac, neuronal, and epithelial spaces, and 6 years at Axol, Steven brings a wealth of expertise to this presentation. By showcasing our hands-on experience and proven methodologies, we can provide valuable insights into how iPSC-derived models can be leveraged for studying such complex diseases, optimizing experimental workflows, and accelerating drug development. This webinar will offer a unique opportunity for you to learn from practical examples, and explore how iPSCs can enhance the human relevance of your own research. We look forward to sharing our work and journey so far in supporting the development of better in vitro models for neurodegenerative diseases such as ALS and AD. Register for the webinar below. Not able to make it? Don't worry, you can still reach out to us at operations@axolbio.com. We'll be happy to have a conversation. #iPSCs #learnwithAxol #Neurodegenerativeresearch #AlzheimersDisease #ALS #linkedInlive

It's #techtuesday and today we are doing something a little different.... Seeing as we will having the 2nd part of our 2-part webinar series this week Wednesday, we would like to extend an invitation to join the webinar and have the opportunity to come ask us questions! Our team will be willing to give a tip or two especially when it relates to the wonderful world of human iPSCs. We look forward to seeing you at the event and answering your questions! Still need to register for the webinar? Click below to register. Not able to make it? Don't worry, you can still reach out to us at operations@axolbio.com. We'll be happy to have a conversation. #techtuesday #iPSCs #livewebinars

Join us this week Wednesday at 4pm (BST) for the 2nd part of our 2-part live webinar series "The challenge of reproducing complex disease models in iPSC-derived cells: Axol’s development of complex disease models" presented by Dr. Steven Broadbent. In this 2nd part of our 2-part webinar, Dr. Steven Broadbent will be detailing some of the practical case studies we have done specifically in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (AD) in creating more complex physiologically relevant human disease models using iPSCs. Dr. Steven Broadbent is the Senior Scientific Support Manager here at Axol Bioscience. With a background in neuroscience, 20 years experience as an Electrophysiologist in the cardiac, neuronal, and epithelial spaces, and 6 years at Axol, Steven brings a wealth of expertise to this presentation. By showcasing our hands-on experience and proven methodologies, we can provide valuable insights into how iPSC-derived models can be leveraged for studying such complex diseases, optimizing experimental workflows, and accelerating drug development. This webinar will offer a unique opportunity for you to learn from practical examples, and explore how iPSCs can enhance the human relevance of your own research. We look forward to sharing our work and journey so far in supporting the development of better in vitro models for neurodegenerative diseases such as ALS and AD. Register for the webinar below. Not able to make it? Don't worry, you can still reach out to us at operations@axolbio.com. We'll be happy to have a conversation. #iPSCs #learnwithAxol #Neurodegenerativeresearch #AlzheimersDisease #ALS #linkedInlive